[1]
Schwasinger-Schmidt TE, Macaluso M. Other Antidepressants. Handbook of experimental pharmacology. 2019:250():325-355. doi: 10.1007/164_2018_167. Epub
[PubMed PMID: 30194544]
[2]
McQuaid JR, Buelt A, Capaldi V, Fuller M, Issa F, Lang AE, Hoge C, Oslin DW, Sall J, Wiechers IR, Williams S. The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals of internal medicine. 2022 Oct:175(10):1440-1451. doi: 10.7326/M22-1603. Epub 2022 Sep 20
[PubMed PMID: 36122380]
Level 1 (high-level) evidence
[3]
Sateia MJ, Buysse DJ, Krystal AD, Neubauer DN, Heald JL. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2017 Feb 15:13(2):307-349. doi: 10.5664/jcsm.6470. Epub 2017 Feb 15
[PubMed PMID: 27998379]
Level 1 (high-level) evidence
[4]
Khouzam HR. A review of trazodone use in psychiatric and medical conditions. Postgraduate medicine. 2017 Jan:129(1):140-148. doi: 10.1080/00325481.2017.1249265. Epub 2016 Oct 28
[PubMed PMID: 27744763]
[5]
Morgenthaler TI, Auerbach S, Casey KR, Kristo D, Maganti R, Ramar K, Zak R, Kartje R. Position Paper for the Treatment of Nightmare Disorder in Adults: An American Academy of Sleep Medicine Position Paper. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2018 Jun 15:14(6):1041-1055. doi: 10.5664/jcsm.7178. Epub 2018 Jun 15
[PubMed PMID: 29852917]
Level 3 (low-level) evidence
[6]
Smales ET, Edwards BA, Deyoung PN, McSharry DG, Wellman A, Velasquez A, Owens R, Orr JE, Malhotra A. Trazodone Effects on Obstructive Sleep Apnea and Non-REM Arousal Threshold. Annals of the American Thoracic Society. 2015 May:12(5):758-64. doi: 10.1513/AnnalsATS.201408-399OC. Epub
[PubMed PMID: 25719754]
[7]
Eckert DJ, Malhotra A, Wellman A, White DP. Trazodone increases the respiratory arousal threshold in patients with obstructive sleep apnea and a low arousal threshold. Sleep. 2014 Apr 1:37(4):811-9. doi: 10.5665/sleep.3596. Epub 2014 Apr 1
[PubMed PMID: 24899767]
[8]
Mandrioli R, Protti M, Mercolini L. New-Generation, Non-SSRI Antidepressants: Therapeutic Drug Monitoring and Pharmacological Interactions. Part 1: SNRIs, SMSs, SARIs. Current medicinal chemistry. 2018:25(7):772-792. doi: 10.2174/0929867324666170712165042. Epub
[PubMed PMID: 28707591]
[9]
Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS drugs. 2012 Dec:26(12):1033-49. doi: 10.1007/s40263-012-0010-5. Epub
[PubMed PMID: 23192413]
[10]
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, Gerlach M, Greiner C, Gründer G, Haen E, Havemann-Reinecke U, Hefner G, Helmer R, Janssen G, Jaquenoud E, Laux G, Messer T, Mössner R, Müller MJ, Paulzen M, Pfuhlmann B, Riederer P, Saria A, Schoppek B, Schoretsanitis G, Schwarz M, Gracia MS, Stegmann B, Steimer W, Stingl JC, Uhr M, Ulrich S, Unterecker S, Waschgler R, Zernig G, Zurek G, Baumann P. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. Pharmacopsychiatry. 2018 Jan:51(1-02):9-62. doi: 10.1055/s-0043-116492. Epub 2017 Sep 14
[PubMed PMID: 28910830]
Level 3 (low-level) evidence
[11]
Odagaki Y, Toyoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. Journal of psychopharmacology (Oxford, England). 2005 May:19(3):235-41
[PubMed PMID: 15888508]
[12]
Wen B, Ma L, Rodrigues AD, Zhu M. Detection of novel reactive metabolites of trazodone: evidence for CYP2D6-mediated bioactivation of m-chlorophenylpiperazine. Drug metabolism and disposition: the biological fate of chemicals. 2008 May:36(5):841-50. doi: 10.1124/dmd.107.019471. Epub 2008 Jan 31
[PubMed PMID: 18238857]
[13]
Kale P, Agrawal YK. Pharmacokinetics of single oral dose trazodone: a randomized, two-period, cross-over trial in healthy, adult, human volunteers under fed condition. Frontiers in pharmacology. 2015:6():224. doi: 10.3389/fphar.2015.00224. Epub 2015 Oct 2
[PubMed PMID: 26483693]
Level 1 (high-level) evidence
[14]
Fiorentini A, Rovera C, Caldiroli A, Arici C, Prunas C, Di Pace C, Paletta S, Pozzoli SM, Buoli M, Altamura AC. Efficacy of oral trazodone slow release following intravenous administration in depressed patients: a naturalistic study. Rivista di psichiatria. 2018 Sep-Oct:53(5):261-266. doi: 10.1708/3000.30005. Epub
[PubMed PMID: 30353201]
[15]
Menza MA. Withdrawal syndrome in a depressed patient treated with trazodone. The American journal of psychiatry. 1986 Sep:143(9):1195
[PubMed PMID: 3752308]
[16]
Nagler EV, Webster AC, Vanholder R, Zoccali C. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP). Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012 Oct:27(10):3736-45. doi: 10.1093/ndt/gfs295. Epub 2012 Aug 1
[PubMed PMID: 22859791]
Level 1 (high-level) evidence
[17]
Einarson A, Bonari L, Voyer-Lavigne S, Addis A, Matsui D, Johnson Y, Koren G. A multicentre prospective controlled study to determine the safety of trazodone and nefazodone use during pregnancy. Canadian journal of psychiatry. Revue canadienne de psychiatrie. 2003 Mar:48(2):106-10
[PubMed PMID: 12655908]
[18]
Saito J, Ishii M, Mito A, Yakuwa N, Kawasaki H, Tachibana Y, Suzuki T, Yamatani A, Sago H, Murashima A. Trazodone Levels in Maternal Serum, Cord Blood, Breast Milk, and Neonatal Serum. Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine. 2021 Nov:16(11):922-925. doi: 10.1089/bfm.2021.0191. Epub 2021 Aug 3
[PubMed PMID: 34348038]
[20]
Viramontes TS, Truong H, Linnebur SA. Antidepressant-Induced Hyponatremia in Older Adults. The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists. 2016 Mar:31(3):139-50. doi: 10.4140/TCP.n.2016.139. Epub
[PubMed PMID: 26975593]
[21]
Haria M, Fitton A, McTavish D. Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. Drugs & aging. 1994 Apr:4(4):331-55
[PubMed PMID: 8019056]
[22]
Santos G, Moreira AM. Distressing Visual Hallucinations after Treatment with Trazodone. Case reports in psychiatry. 2017:2017():6136914. doi: 10.1155/2017/6136914. Epub 2017 Jun 18
[PubMed PMID: 28702268]
Level 3 (low-level) evidence
[23]
Hu J, Lai J, Zheng H, Hu S, Xu Y. Fan the flame: trazodone-induced mania in a unipolar depressed patient with stable sertraline treatment. Neuropsychiatric disease and treatment. 2017:13():2251-2254. doi: 10.2147/NDT.S143965. Epub 2017 Aug 24
[PubMed PMID: 28883733]
[24]
Bixby AL, VandenBerg A, Bostwick JR. Clinical Management of Bleeding Risk With Antidepressants. The Annals of pharmacotherapy. 2019 Feb:53(2):186-194. doi: 10.1177/1060028018794005. Epub 2018 Aug 6
[PubMed PMID: 30081645]
[25]
Kurian BT, Ray WA, Arbogast PG, Fuchs DC, Dudley JA, Cooper WO. Effect of regulatory warnings on antidepressant prescribing for children and adolescents. Archives of pediatrics & adolescent medicine. 2007 Jul:161(7):690-6
[PubMed PMID: 17606833]
[26]
Amari DT, Juday T, Frech FH, Wang W, Wu Z, Atkins N Jr, Wickwire EM. Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines. BMC geriatrics. 2022 Jun 4:22(1):484. doi: 10.1186/s12877-022-03165-6. Epub 2022 Jun 4
[PubMed PMID: 35658904]
[27]
Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ. Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem. Clinical pharmacology and therapeutics. 2009 Jun:85(6):644-50. doi: 10.1038/clpt.2008.293. Epub 2009 Feb 25
[PubMed PMID: 19242403]
[28]
Otani K, Ishida M, Kaneko S, Mihara K, Ohkubo T, Osanai T, Sugawara K. Effects of carbamazepine coadministration on plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine. Therapeutic drug monitoring. 1996 Apr:18(2):164-7
[PubMed PMID: 8721280]
[29]
Carvalhana S, Oliveira A, Ferreira P, Resende M, Perdigoto R, Barroso E. Acute Liver Failure due to Trazodone and Diazepam. GE Portuguese journal of gastroenterology. 2017 Jan:24(1):40-42. doi: 10.1159/000450878. Epub 2016 Nov 16
[PubMed PMID: 28848778]
[30]
Jarema M, Dudek D, Landowski J, Heitzman J, Rabe-Jabłońska J, Rybakowski J. [Trazodon--the antidepressant: mechanism of action and its position in the treatment of depression]. Psychiatria polska. 2011 Jul-Aug:45(4):611-25
[PubMed PMID: 22232986]
[31]
Rauch PK, Jenike MA. Digoxin toxicity possibly precipitated by trazodone. Psychosomatics. 1984 Apr:25(4):334-5
[PubMed PMID: 6718667]
[32]
Small NL, Giamonna KA. Interaction between warfarin and trazodone. The Annals of pharmacotherapy. 2000 Jun:34(6):734-6
[PubMed PMID: 10860134]
[33]
Jurek L, Nourredine M, Megarbane B, d'Amato T, Dorey JM, Rolland B. [The serotonin syndrome: An updated literature review]. La Revue de medecine interne. 2019 Feb:40(2):98-104. doi: 10.1016/j.revmed.2018.08.010. Epub 2018 Sep 20
[PubMed PMID: 30243558]
[34]
Avila JD. Fatal Cerebral Edema, Seizures, and Hyponatremia After Trazodone Overdose. Clinical neuropharmacology. 2017 Sep/Oct:40(5):221-223. doi: 10.1097/WNF.0000000000000235. Epub
[PubMed PMID: 28816830]
[35]
Wen CC, Munarriz R, McAuley I, Goldstein I, Traish A, Kim N. Management of ischemic priapism with high-dose intracavernosal phenylephrine: from bench to bedside. The journal of sexual medicine. 2006 Sep:3(5):918-922. doi: 10.1111/j.1743-6109.2005.00140.x. Epub
[PubMed PMID: 16942536]